| Dermatología JL Bolognia, JV Schaffer, L Cerroni Elsevier Health Sciences, 2018 | 410* | 2018 |
| Pediculosis CJ Ko, DM Elston Journal of the American Academy of Dermatology 50 (1), 1-12, 2004 | 311 | 2004 |
| Granulysin, a T cell product, kills bacteria by altering membrane permeability WA Ernst, S Thoma-Uszynski, R Teitelbaum, C Ko, DA Hanson, ... The Journal of Immunology 165 (12), 7102-7108, 2000 | 275 | 2000 |
| Inflammatory eruptions associated with immune checkpoint inhibitor therapy: a single-institution retrospective analysis with stratification of reactions by toxicity and … E Coleman, C Ko, F Dai, MM Tomayko, H Kluger, JS Leventhal Journal of the American Academy of Dermatology 80 (4), 990-997, 2019 | 153 | 2019 |
| The effect of share repurchase on the value of the firm E Elton, M Gruber The Journal of finance 23 (1), 135-149, 1968 | 140* | 1968 |
| Dermatopathology E-book D Elston, T Ferringer, CJ Ko, S Peckham, WA High, DJ DiCaudo Elsevier Health Sciences, 2013 | 137 | 2013 |
| GNA14 somatic mutation causes congenital and sporadic vascular tumors by MAPK activation YH Lim, A Bacchiocchi, J Qiu, R Straub, A Bruckner, L Bercovitch, ... The American Journal of Human Genetics 99 (2), 443-450, 2016 | 128 | 2016 |
| Predicting non-melanoma skin cancer via a multi-parameterized artificial neural network D Roffman, G Hart, M Girardi, CJ Ko, J Deng Scientific reports 8 (1), 1701, 2018 | 104 | 2018 |
| Keratoacanthoma: facts and controversies CJ Ko Clinics in dermatology 28 (3), 254-261, 2010 | 104 | 2010 |
| Immune-related sarcoidosis observed in combination ipilimumab and nivolumab therapy KC Suozzi, M Stahl, CJ Ko, A Chiang, SN Gettinger, MD Siegel, ... JAAD case reports 2 (3), 264-268, 2016 | 93 | 2016 |
| Hidradenocarcinoma: a histological and immunohistochemical study CJ Ko, AJ Cochran, W Eng, SW Binder Journal of cutaneous pathology 33 (11), 726-730, 2006 | 84 | 2006 |
| Somatic activating RAS mutations cause vascular tumors including pyogenic granuloma YH Lim, SR Douglas, CJ Ko, RJ Antaya, JM McNiff, J Zhou, KA Choate, ... The Journal of investigative dermatology 135 (6), 1698, 2015 | 81 | 2015 |
| Spontaneous tumour regression in keratoacanthomas is driven by Wnt/retinoic acid signalling cross-talk G Zito, I Saotome, Z Liu, EG Ferro, TY Sun, DX Nguyen, K Bilguvar, CJ Ko, ... Nature communications 5 (1), 3543, 2014 | 69 | 2014 |
| Intensity-modulated proton therapy for elective nodal irradiation and involved-field radiation in the definitive treatment of locally advanced non–small-cell lung cancer: a … AH Kesarwala, CJ Ko, H Ning, E Xanthopoulos, KE Haglund, WP O'Meara, ... Clinical lung cancer 16 (3), 237-244, 2015 | 64 | 2015 |
| Second-hit, postzygotic PMVK and MVD mutations in linear porokeratosis L Atzmony, HM Khan, YH Lim, AS Paller, JL Levinsohn, KE Holland, ... JAMA dermatology 155 (5), 548-555, 2019 | 63 | 2019 |
| Inverse psoriasiform eruption during pembrolizumab therapy for metastatic melanoma MB Totonchy, HH Ezaldein, CJ Ko, JN Choi JAMA dermatology 152 (5), 590-592, 2016 | 62 | 2016 |
| Fibrillar IgA deposition in dermatitis herpetiformis–an underreported pattern with potential clinical significance CJ Ko, OR Colegio, JE Moss, JM McNiff Journal of cutaneous pathology 37 (4), 475-477, 2010 | 51 | 2010 |
| Unguioblastoma and unguioblastic fibroma–an expanded spectrum of onychomatricoma CJ Ko, L Shi, RJ Barr, L Mölne, A Ternesten‐Bratel, JT Headington Journal of cutaneous pathology 31 (4), 307-311, 2004 | 51 | 2004 |
| Actinic keratosis: facts and controversies CJ Ko Clinics in dermatology 28 (3), 249-253, 2010 | 50 | 2010 |
| Discordant anti‐SARS‐CoV‐2 spike protein and RNA staining in cutaneous perniotic lesions suggests endothelial deposition of cleaved spike protein CJ Ko, M Harigopal, JR Gehlhausen, M Bosenberg, JM McNiff, W Damsky Journal of Cutaneous Pathology 48 (1), 47-52, 2021 | 47 | 2021 |
